News

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Appoints Dr. Eldon R. Smith to Board of Directors
Successful ASSERT Trial Results in Resverlogix Filing New RVX-208 Patent
Resverlogix Notice of Conference Call & Webcast to Provide a Market Update
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
Resverlogix's Phase 2 ASSURE Trial Amended
Resverlogix Surpasses $1 Billion Trading Milestone
Resverlogix Closes Equity Offering
Resverlogix Scientific Data Presented at EAS Congress
Resverlogix Announces CDN $10 Million Equity Offering
Resverlogix Settles Draw Down on Standby Equity Distribution Agreement
Resverlogix Closes Equity Offering
Resverlogix Confirms CDN $9.2 Million Offering
Resverlogix Announces Financing
Resverlogix Announces Intention to Draw Down $1 Million on Standby Equity Distribution Agreement
Resverlogix Completes Dosing for ASSERT Trial
Resverlogix Notice of Conference Call & Webcast for Year End Update
Resverlogix Scientific Data Presented at ATVB Conference
Resverlogix Activates Standby Equity Distribution Agreement
Resverlogix Update
Resverlogix Market Update
Resverlogix Activates First Site for ASSURE 1 Clinical Trial
Recruitment Completed for ASSERT
Bayer HealthCare CEO to Join RVX
RVX Closes Additional $8 Million
JP Morgan Healthcare Conference & Biotech Showcase
Repurchase of Debenture Debt